Tuesday, 21 February 2017

BLIS Technology Ordinary Shares

NZX : BLT

0.0440
21 Feb 17 15:51
Change:
 0.00
Open:
0.0450
High:
0.0450
Ask:
0.0440
Volume:
695,000
Change(%):
0.00
Prev:
0.0440
Low:
0.0430
Bid:
0.0430
Avg vol:
0
Profile
BLIS Technologies Limited develops, manufactures, and sells products and ingredients for the oral healthcare market worldwide. The company develops products based on strains of bacteria that produce Bacteriocin-Like Inhibitory Substances (BLIS). Its products include BLIS K12 Throat Guard Daily and BLIS K12 Throat Guard Boost that support throat?s natural defenses against undesirable bacteria; BLIS K12 RapidEze Gargle, which assists the throat?s natural defences by fighting undesirable bacteria associated with winter ill?s and chills; BLIS K12 Travel Guard that supports the throat's natural immune defense system; BLIS Bio Restore, a course of selected intestinal and oral bacteria, which restores and promotes health by restoring the body?s natural microbial balance; and BLIS K12 Fresh Breath Kit for treating chronic bad breath sufferers. The company is based in Dunedin, New Zealand.
Summary
Shares:1,107,654,000
Issuer:BLIS Technologies Limited
Solicitor:Kensington Swan Wellington
Registry:LINK MARKET SERVICES LIMITED
Auditor:Deloitte Dunedin
Settlement:NZCDC Settlement System
Website:http://www.blis.co.nz/
Fundamentals
Market Cap:$48,736,776
52 wk High:0.0610
52 wk Low:0.0250
Sector:Investment
NTA:0.0200
Address
BLIS Technology
Centre for Innovation PO Box 56
87 St David Street
Dunedin, 9016
New Zealand
Latest News
Announcements
  • Blis Technologies Limited- NZX Release

    09:18 | 20/2/17
    NZX
    Updated guidance Blis Technologies reports that it now does not expect to meet its previous guidance of net profit before tax in excess of $700,000. However, the company does  more»
  • Study Results - BLIS K12 Probiotic- Strep Throat

    14:26 | 13/2/17
    NZX
    MEDIA RELEASE February 13, 2017. Study results show K12 probiotic helps prevent rheumatic fever As the Government launches a new rheumatic fever awareness campaign this w more»
  • SSH Notice - Minchun Qiu

    10:54 | 8/2/17
    NZX
    Disclosure of ceasing to have substantial holding Section 279, Financial Markets Conduct Act 2013 Note: This form must be completed in accordance with the instructions at the en more»
  • SSH Notice - Wen Wu

    10:54 | 8/2/17
    NZX
    Disclosure of movement of 1% or more in substantial holding or change in nature of relevant interest, or both Sections 277 and 278, Financial Markets Conduct Act 2013 Note: This more»
  • New European study

    09:27 | 23/1/17
    NZX
    MEDIA RELEASE January 23, 2017. New European study shows benefits of Kiwi-developed probiotic in young children A recent study by Italy''s pre-eminent researcher into probi more»
There are currently no comments on this topic.
Be the first person to Add a Comment...
Add a Comment
You must be a registered user to post a comment: REGISTER NOW
If you are already registered, please LOGIN NOW
Global Indices
CodeLastChange
NZ507,116160.23%
COMP5,839240.41%
DJI20,62440.02%
SP5002,35140.17%
DAX11,828710.60%
FTSE7,30000.00%
NI22519,3811300.68%
TWI77.180.150.19%
Currencies
CodeLastChange
EURUSD1.0580.0030.27%
NZDUSD0.71580.00260.36%
AUDUSD0.76680.00220.29%
NZDAUD0.93330.00120.13%